FTC Dems’ view on pharma deal raises eyebrows
The Federal Trade Commission’s approval of Bristol-Myers Squibb/Celgene last week drew opposition from its Democratic members, worrying some antitrust lawyers about an ideological divide but winning praise from other competition experts.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10